Pharmacogenetic information in Swiss drug labels – a systematic analysis
| Autor: | Teri E. Klein, Li Gong, Michelle Whirl-Carrillo, Chiara Jeiziner, Katja Suter, T D Szucs, H. E. Meyer zu Schwabedissen, Kurt E. Hersberger, U Wernli, Julia M. Barbarino |
|---|---|
| Rok vydání: | 2020 |
| Předmět: |
Drug
medicine.medical_specialty PharmGKB Drug-Related Side Effects and Adverse Reactions media_common.quotation_subject MEDLINE Predictive markers 030226 pharmacology & pharmacy Article 03 medical and health sciences Gene therapy 0302 clinical medicine Health care Genetics Humans Medicine Medical physics Drug reaction Drug Labeling media_common Pharmacology business.industry technology industry and agriculture Drug regulation Pharmacogenomic Testing Pharmaceutical care Pharmaceutical Preparations Pharmacogenetics 030220 oncology & carcinogenesis Molecular Medicine business Switzerland |
| Zdroj: | The Pharmacogenomics Journal |
| ISSN: | 1473-1150 1470-269X |
| DOI: | 10.1038/s41397-020-00195-4 |
| Popis: | Implementation of pharmacogenetics (PGx) and individualization of drug therapy is supposed to obviate adverse drug reactions or therapy failure. Health care professionals (HCPs) use drug labels (DLs) as reliable information about drugs. We analyzed the Swiss DLs to give an overview on the currently available PGx instructions. We screened 4306 DLs applying natural language processing focusing on drug metabolism (pharmacokinetics) and we assigned PGx levels following the classification system of PharmGKB. From 5979 hits, 2564 were classified as PGx-relevant affecting 167 substances. 55% (n = 93) were classified as “actionable PGx”. Frequently, PGx information appeared in the pharmacokinetics section and in DLs of the anatomic group “nervous system”. Unstandardized wording, appearance of PGx information in different sections and unclear instructions challenge HCPs to identify and interpret PGx information and translate it into practice. HCPs need harmonization and standardization of PGx information in DLs to personalize drug therapies and tailor pharmaceutical care. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Full text from SpringerLink